Biodegradable polymer drug-eluting stents versus first-generation durable polymer drug-eluting stents

A systematic review and meta-analysis of 12 randomized controlled trials

Pravesh Kumar Bundhun, MD\textsuperscript{a}, Manish Parsun, MBBS\textsuperscript{b}, Feng Huang, MD\textsuperscript{c,*}

Abstract

Background: Even if drug-eluting stents (DES) showed beneficial effects in patients with coronary artery diseases (CADs), limitations have been observed with the first-generation durable polymer DES (DP-DES). Recently, biodegradable polymer DES (BP-DES) have been approved to be used as an alternative to DP-DES, with potential benefits. We aimed to systematically compare BP-DES with the first-generation DP-DES using a large number of randomized patients.

Methods: Electronic databases were searched for randomized controlled trials (RCTs) comparing BP-DES with first-generation DP-DES. The main endpoints were the long-term (≥2 years) adverse clinical outcomes that were reported with these 2 types of DES. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) and the analysis was carried out by RevMan 5.3 software.

Results: Twelve trials with a total number of 13,480 patients (7730 and 5750 patients were treated by BP-DES and first-generation DP-DES, respectively) were included. During a long-term follow-up period of ≥2 years, mortality, myocardial infarction (MI), target lesion revascularization (TLR), and major adverse cardiac events (MACEs) were not significantly different between these 2 groups with OR: 0.84, 95% CI: 0.66–1.07; P = .16, I\textsuperscript{2} = 0%, OR: 1.01, 95% CI: 0.45–2.27; P = .98, I\textsuperscript{2} = 0%, OR: 0.91, 95% CI: 0.75–1.11; P = .37, I\textsuperscript{2} = 0% and OR: 0.86, 95% CI: 0.44–1.67; P = .65, I\textsuperscript{2} = 0%, respectively. Long-term total stent thrombosis (ST), definite ST, and probable ST were also not significantly different between BP-DES and the first-generation DP-DES with OR: 0.77, 95% CI: 0.50–1.18; P = .22, I\textsuperscript{2} = 0%, OR: 0.71, 95% CI: 0.43–1.18; P = .19, I\textsuperscript{2} = 0% and OR: 1.31, 95% CI: 0.56–3.08; P = .53, I\textsuperscript{2} = 6%, respectively.

Conclusion: Long-term mortality, MI, TLR, MACEs, and ST were not significantly different between BP-DES and the first-generation DP-DES. However, the follow-up period was restricted to only 3 years in this analysis.

Abbreviations: BP-DES = biodegradable polymer drug-eluting stents, DES = drug-eluting stents, DP-DES = durable polymer drug-eluting stents, MACEs = major adverse cardiac events, PCI = percutaneous coronary intervention, RCTs = randomized controlled trials, ST = stent thrombosis.

Keywords: biodegradable polymer drug-eluting stents, durable polymer drug-eluting stents, long-term, major adverse cardiac events, randomized controlled trials, stent thrombosis
1. Introduction

Drug-eluting stents (DES) showed beneficial effects in patients with coronary artery diseases (CADs). However, limitations have been observed with the first-generation durable polymer DES (DP-DES), which are thick, and might be among the factors, which are associated with the initiation of vascular inflammatory reactions, therefore, contributing to the occurrence of late stent thrombosis (ST).

Recently, biodegradable polymer DES (BP-DES) have been approved to be used as an alternative to DP-DES, with potential benefits. BP-DES carry and control the drug, which is being released from DES during a specific period of time, and then erode and vanish from the vascular surface.

In other words, DES that are currently approved for use consist of a durable polymer (i.e., why they are called DP-DES), which is permanently attached to the stent even after the drug is eluted. Hence, the risk of ST becomes accountable when the polymer is removed and a bare metal like stent is left in order to reduce late ST.[1]

Insights from the 5 years follow-up of the randomized PAINT trial comparing very late outcomes of DES coated with biodegradable polymers releasing either paclitaxel or sirolimus showed that compared with bare metal stents (BMS), BP-DES were more effective in reducing major adverse cardiac events (MACEs) and reintervention without causing any increase in ST.[2] In contrast, even if the first-generation DP-DES significantly decreased repeated revascularization when compared with BMS, they were associated with significantly higher incidence of very late ST.[3]

Nevertheless, BP-DES have seldom been compared with the first-generation DP-DES [sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES)] through meta-analyses. Hence, we aimed to systematically compare BP-DES with the first-generation DP-DES using a large number of randomized patients.

2. Methods

2.1. Data sources and search strategy

PubMed/Medline, EMBASE, and the Cochrane library were searched for randomized controlled trials (RCTs) comparing BP-DES with the first-generation DP-DES (SES or PES) through meta-analyses. Hence, we aimed to systematically compare BP-DES with the first-generation DP-DES using a large number of randomized patients.

2.2. Inclusion and exclusion criteria

Studies were included if

(1) They were published trials comparing BP-DES with the first-generation DP-DES (SES or PES);
(2) They reported adverse clinical outcomes as their endpoints.

Studies were excluded if

(1) They were non-RCTs (meta-analyses, observational studies, letter to editors);
(2) They did not report adverse clinical outcomes as their endpoints;
(3) They were duplicates;
(4) They were associated with the same trial.

2.3. Definitions, outcomes, and follow ups

The following adverse outcomes were analyzed:

(1) Mortality (all-cause mortality);
(2) Myocardial infarction (MI);
(3) Target vessel revascularization (TVR);
(4) Target lesion revascularization (TLR);
(5) MACEs;
(6) ST including total ST, definite ST, and probable ST. Total ST consisted of any type of ST, whereas definite and probable ST were defined according to the Academic Research Consortium (ARC).[4]

The main focus of this analysis was on the outcomes that were reported during a longer follow-up period of ≥2 years. However, outcomes were also analyzed during a mean follow-up period ranging from 8 months to 3 years and during a mid-term follow-up period of less than or equal to 1 year (≤1 year). Table 1 summarized the outcomes that were reported among the trials with their corresponding follow-up periods and Table 2 summarized the types of participants and the antiplatelet regimens which were used.

---

Table 1

| Trials             | Outcomes                              | Follow-up periods |
|--------------------|---------------------------------------|------------------|
| Sham et al[10]     | Death, TLR, definite and probable ST  | 2 y              |
| COSTAR R[11]       | MACEs, death, MI, TVR                 | 8 mo             |
| HOPE[12]           | MACEs, death, MI, TLR, definite/probable ST | 1–3 y          |
| I LOVE IT 2[13]    | Death, MI, TVR, definite ST, probable ST | 1 y            |
| ISAR TEST 2[14]    | MI, death, TLR, definite and probable ST | 1 and 2 y      |
| ISAR TEST 4[15]    | Death, TLR, definite and probable ST  | 3 y              |
| LEADERS[16]        | Death, MI, TLR, definite and probable ST | 3 y            |
| NOBORI[17]         | Death, MI, TLR, MACEs, ST             | 10 mo            |
| Nobori DES[18]     | Death, MI, TLR, TVR, MACEs, definite or probable ST | 9 mo    |
| NOYA[19]           | Death, MI, TLR, MACEs, ST             | 2 y              |
| RESOLVE[20]        | Death, MI, TLR, MACEs, ST             | 1 y              |
| SURE OUT[21]       | Death, MI, TLR, probable ST           | 1 y              |

MACEs = major adverse cardiac events, MI = myocardial infarction, ST = stent thrombosis, TLR = target lesion revascularization, TVR = target vessel revascularization.
**Table 2**

| Trials            | Anti-platelet regimen used | Types of participants included                                                                 | Anti-proliferative agent used in each BP-DES |
|-------------------|---------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------|
| Shen et al[5]     | Aspirin + clopidogrel     | Any patient with SCAD or patients with acute MI ≥ 2 wks                                        | Arsenic trioxide                            |
| COSTAR II         | Aspirin + clopidogrel, or warfarin + aspirin in specific subgroup | Patients with SCAD, or patients with MI ≥ 72 h                                                   | Paclitaxel                                  |
| HOPE              | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | Sirolimus                                   |
| I LOVE IT 2[2]    | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | Sirolimus                                   |
| ISAR TEST 3[10]   | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | Limus                                      |
| ISAR TEST 4[10]   | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | Biolimus                                    |
| NOYAI             | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | NOYAI Sirolimus                             |
| Nobori DES        | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | Nobori Sirolimus                            |
| RESOLVE[15]       | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | NOYAI Sirolimus                             |
| SORT OUT V[16]    | Aspirin + clopidogrel     | Patients with SCAD, or patients with STEMI ≥ 1 wk                                               | Biolimus                                    |

ACS = acute coronary syndrome, AMI = acute myocardial infarction, BP-DES = biodegradable polymer drug-eluting stents, MI = myocardial infarction, SCAD = stable chronic coronary artery disease, STEMI = ST-elevation myocardial infarction.

2.4. Data extraction and quality assessment

Two authors (PKB and MP) independently assessed the trials that were confirmed for this analysis. Information regarding the trial names, the year of publications, the total number of patients classified in the BP-DES, and first-generation DP-DES groups, respectively, relevant data associated with the baseline characteristics of the patients, the types of first-generation DP-DES involved, the reported clinical outcomes with the corresponding number of events, and the follow-up periods were carefully extracted. Disagreements about including certain data were carefully discussed between these 2 authors. However, if they could not reach a consensus, disagreements were further resolved by the third author (FH). The bias risks were assessed using the recommendations approved by the Cochrane Collaborations[17] whereby a grade ranging from A to E was allotted to the trials depending on the level of bias that was involved (Table 3).

2.5. Methodological and statistical analysis

Recommendations of the PRISMA[18] (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement were followed. Heterogeneity across the trials was assessed using the Cochrane Q-statistic test whereby a P value of ≤ 0.05 was considered statistically significant. Heterogeneity was also assessed by the I²-statistic test whereby a low percentage of I² denoted a low heterogeneity while an increasing percentage denoted an increasing heterogeneity. If I² was less than 50%, a fixed effects model was used. However, if I² was more than 50%, a random effects model was used. We calculated odds ratios (OR) with 95% confidence intervals (CIs) and the pooled analyses were performed with RevMan 5.3 software.

Sensitivity analyses were carried out for the subgroups assessing the long-term follow up (≥ 2 years). The trials were excluded one by one and a new analysis was performed each time, to find out if there was any significant change in the results. This current analysis did not involve a large number of trials; therefore, Egger or Begg tests were not considered necessary to assess publication bias. Instead, publication bias was visually estimated by assessing funnel plots that were obtained from the Revman software (normally for smaller volume of studies, funnel plots obtained from Revman are recommended to assess publication bias).

**Table 3**

| Trials            | Type of DP-DES | Bias risk grade | Year of publication | No. of patients in BP-DES (n) | No. of patients in DP-DES (n) |
|-------------------|----------------|-----------------|---------------------|------------------------------|-------------------------------|
| Shen et al[5]     | SES            | B               | 2015                | 105                          | 107                           |
| COSTAR II         | PES            | B               | 2008                | 989                          | 686                           |
| HOPE[7]           | SES            | B               | 2014                | 142                          | 145                           |
| I LOVE IT 2[2]    | SES            | B               | 2014                | 1818                         | 905                           |
| ISAR TEST 3[10]   | SES            | B               | 2009                | 202                          | 202                           |
| ISAR TEST 4[10]   | SES            | B               | 2011                | 1299                         | 652                           |
| LEADERS[11]       | SES            | B               | 2011                | 857                          | 850                           |
| Nobori DES[13]    | SES            | B               | 2012                | 153                          | 90                            |
| NOYAI F[14]       | SES            | B               | 2012                | 150                          | 150                           |
| RESOLVE[15]       | SES            | B               | 2014                | 596                          | 596                           |
| SORT OUT V[16]    | SES            | B               | 2013                | 1229                         | 1239                          |
| Total no. of patients (n) |               |                 |                     | 7730                         | 5750                          |

BP-DES = biodegradable polymer drug-eluting stents, DP-DES = durable polymer drug-eluting stents, PES = paclitaxel-eluting stents, SES = sirolimus-eluting stents.
2.6. Ethical approval

Ethical approval was not necessary, as this was a systematic review and meta-analysis of randomized trials.

3. Results

3.1. Search outcomes

Nine hundred sixty-five articles were obtained from electronic databases in addition to 25 more articles that were obtained from the reference lists of suitable studies. After a careful assessment of the titles and abstracts, 901 articles were eliminated, as they were not related to the topic of this research. A further 57 articles were eliminated, as they were duplicates. Thirty-two (32) full-text articles were assessed for eligibility. A further 20 articles were eliminated, as 8 articles were observational studies, 5 articles were meta-analyses, 2 articles were letter to editors, and 5 other articles involved the same trials. Finally, 12 trials[5–16] were selected and included in this systematic review and meta-analysis as shown in Fig. 1.

3.2. General features of the trials

A total number of 13,480 patients (7730 patients who were treated with BP-DES and 5750 patients who were treated with the first-generation DP-DES) were included in this analysis. Further details about the total number of patients retrieved from each trial, the publication year, and the types of first-generation DP-DES (SES or PES) involved have been listed in Table 3.

3.3. Baseline characteristics of the patients

The baseline features of the patients have been summarized in Tables 4 and 5. The mean age of the patients who were treated by BP-DES ranged from 56.6 to 67.1 years, whereas the mean age of the patients who were treated by DP-DES ranged from 56.7 to 67.7 years. The number of male patients were above 66% in all the trials who were included. Trial HOPE had the least number of patients suffering from hypertension (54.9% vs 48.3% for BP-DES and DP-DES, respectively), RESOLVE trial had the least number of patients suffering from dyslipidemia (14.6% vs 12.6% for BP-DES and DP-DES, respectively), whereas the study by

---

**Figure 1.** Flow diagram representing the study selection. Twelve trials that satisfied the inclusion and exclusion criteria of this study were finally included in this analysis.
Shen et al[7] had the highest number of patients suffering from dyslipidemia. Trial Nobori DES consisted of the largest number of patients with diabetes mellitus (38.7% vs 39.4% for BP-DES and DP-DES respectively). Most of the patients were being treated by elective PCI. According to these features, no significant differences were observed among patients who were implanted with BP-DES and the first-generation DP-DES.

3.4. Adverse clinical outcomes that were reported during a follow-up period ranging from 8 months to 3 years

Results of this analysis showed that during a mean follow-up period ranging from 8 months to 3 years, mortality, MI, TLR, MACEs, and TVR were not significantly different between the BP-DES and first-generation DP-DES groups with OR: 0.91, 95% CI: 0.76–1.10; P = .33, I² = 0%, OR: 1.08, 95% CI: 0.88–1.34; P = .46, I² = 0%, OR: 0.94, 95% CI: 0.79–1.11; P = .45, I² = 44%; OR: 1.19, 95% CI: 0.95–1.49; P = .14, I² = 41% and OR: 1.23; 95% CI: 0.86–1.75; P = .26, I² = 60%, respectively. Total ST, definite ST, and probable ST were also not significantly different between the BP-DES and first-generation DP-DES groups with OR: 0.75, 95% CI: 0.54–1.04; P = .09, I² = 16%; OR: 0.85, 95% CI: 0.55–1.32; P = .47, I² = 35% and OR: 1.26, 95% CI: 0.60–2.63; P = .54, I² = 0%, respectively. These results have been illustrated in Figs. 2 and 3.

STs were further subdivided into acute ST, subacute ST, and late ST and then analyzed. Our results showed no significant difference observed with OR: 1.00, 95% CI: 0.43–2.33; P = .99, I² = 23% for acute ST, OR: 1.12, 95% CI: 0.54–2.36; P = .76, I² = 24% for subacute ST and OR: 0.58, 95% CI: 0.28–1.18; P = .13, I² = 0% for late ST (Fig. 4).

Another subgroup analysis was carried out, excluding patients with PES (COSTAR II and Nobori DES). When only patients implanted with SES were analyzed, there was still no significant change in the results. Mortality, MI, TVR, TLR, MACEs, and total ST were still not significantly different with BP-DES and SES with OR: 0.91, 95% CI: 0.75–1.10; P = .33, I² = 0%, OR: 1.01, 95% CI: 0.81–1.28; P = .91, I² = 0%, OR: 1.05, 95% CI: 0.84–1.30; P = .68, I² = 37%, OR: 0.95, 95% CI: 0.81–1.13; P = .59, I² = 38%, OR: 0.91, 95% CI: 0.67–1.23; P = .54, I² = 0% and OR: 0.74, 95% CI: 0.54–1.03; P = .08, I² = 23% respectively (Fig. 5).

3.5. Adverse clinical outcomes reported during the 1-year follow-up (mid-term)

During a follow-up of 1 year or less, mortality and MI were not significantly different between the BP-DES and first-generation DP-DES with OR: 0.99, 95% CI: 0.75–1.30; P = .96, I² = 0% and OR: 1.07, 95% CI: 0.83–1.38; P = .60, I² = 60%,
respectively. Total ST and probable ST were also not significantly different between these 2 groups with OR: 0.70, 95% CI: 0.43–1.14; P = .15, I² = 0% and OR: 1.10, 95% CI: 0.25–4.90; P = .90, I² = 0%, respectively. However, TVR significantly favored first-generation DP-DES with OR: 1.47, 95% CI: 1.15–1.87; P = .002, I² = 24% (Fig. 6). Moreover, TLR, MACEs, and definite ST were also not significantly different with OR: 0.84, 95% CI: 0.50–1.41; P = .51, OR: 1.17, 95% CI: 0.77–1.78; P = .46, and OR: 1.30, 95% CI: 0.11–15.47; P = .84, respectively. These results have been summarized in Table 6 and illustrated in Fig. 7.

![Figure 2](image-url)

Figure 2. Comparing BP-DES with first-generation DP-DES during a follow-up period of 8 months to 3 years (part 1). No significant difference was observed between BP-DES and first-generation DP-DES as shown in the figure.
3.6. Adverse clinical outcomes reported at ≥2 years (long-term)

Outcomes were also analyzed during a long-term follow-up period of 2 or more years (involving 4855 patients). The results showed that mortality, MI, TLR, and MACEs were still not significantly different between these 2 groups with OR: 0.84, 95% CI: 0.66–1.07; P = .16, I² = 0%, OR: 1.01, 95% CI: 0.45–2.27; P = .98, I² = 0%; OR: 0.91, 95% CI: 0.75–1.11; P = .37, I² = 0%, and OR: 0.86, 95% CI: 0.44–1.67; P = .65, I² = 0%, respectively. Long-term total ST, definite ST, and probable ST were also not significantly different between BP-DES and first-generation DP-DES with OR: 0.77, 95% CI: 0.50–1.20; P = .22, I² = 0%; OR: 0.71, 95% CI: 0.43–1.18; P = .19, I² = 0%, and OR: 1.31, 95% CI: 0.96–1.66; P = .53, I² = 0% respectively. These results have been summarized in Table 7 and represented in Fig. 8.

3.7. Sensitivity analysis

For all of the above analyses, sensitivity analyses were carried out and yielded consistent results. For the long-term follow-up (≥2 years), all the trials were excluded one by one and a new analysis was carried out each time, to find out whether there was any significant change in the results. However, no significant difference was observed and consistent results were obtained.

When trial HOPE was excluded during the long-term (≥2 years) follow-up, mortality, TLR, and total ST were still not significantly different with OR: 0.88, 95% CI: 0.56–1.39; P = .34, OR: 1.09, 95% CI: 0.73–1.63; P = .66, OR: 0.87, 95% CI: 0.71–1.07; P = .18, and OR: 0.83, 95% CI: 0.55–1.23; P = .48, respectively. When trial ISAR TEST 3 was excluded, no significant difference was observed. The same thing was observed when trial ISAR TEST 4 was excluded. Mortality, TLR, and total ST were not significantly different with OR: 0.84, 95% CI: 0.56–1.26; P = .40,
In this analysis, we aimed to show whether the long-term adverse outcomes, which were associated with BP-DES, were significantly different when compared with those associated with first-generation DP-DES.

Current results showed that during a longer follow-up period, mortality, MI, MACEs, and TLR were not significantly different.
between BP-DES and the first-generation DES. Total ST, definite ST, and probable ST were also not significantly different between BP-DES and durable polymer SES or PES.

A recent meta-analysis involving 3 randomized trials with SES and everolimus-eluting stents (EES), respectively, and 1 trial with PES, comparing BP-DES with DP-DES, also showed that MACEs were not significantly different between these 2 groups, but however, BP-DES were associated with a significantly lower rate of very late ST than DP-DES.[19] Another meta-analysis involving 15 randomized trials comparing BP-DES with DP-DES during a mean follow-up period of 20.6 months showed that both types of stents were equally effective and safe to use.[20] However, in exception to the inclusion of SES and PES, it also involved 4 trials with EES. In addition, the authors suggested further long-term studies to confirm their results.

Also, the updated meta-analysis by Wang et al[21] also showed similar clinical benefits between BP-DES and first-generation DES, and BP-DES were also not significantly different between BP-DES and durable polymer SES or PES.

### Table 6

| Outcomes analyzed | OR with 95% CI | P | \( \hat{p} \) (%) |
|-------------------|----------------|---|---------------|
| Mortality         | 0.99 [0.75-1.30]| .06| 0             |
| MI                | 1.07 [0.83-1.38]| .60| 0             |
| TVR               | 1.47 [1.15-1.89] | .002| 24           |
| TLR               | 0.84 [0.50-1.41] | .51| 58            |
| MACEs             | 1.17 [0.77-1.78] | .46| 51            |
| Total ST          | 0.70 [0.43-1.14] | .15| 42            |
| Definite ST       | 1.20 [1.11-1.55] | .04| 91            |
| Probable ST       | 1.10 [0.25-4.00] | .00| 0             |

\( \hat{p} \) = confidence interval, MACEs = major adverse cardiac events, MI = myocardial infarction, OR = odds ratios, ST = stent thrombosis, TLR = target lesion revascularization, TVR = target vessel revascularization.
DP-DES. However, as only 5 randomized trials were included, the authors concluded that the incidence of very late ST should be confirmed in other future studies. Even though a total number of 12 randomized trials were included in this current analysis, our results were similar with that of the study published by Wang et al.\[21\] Excluding data that were obtained from randomized trials, even an observational study comparing BP-DES with DP-DES showed comparable adverse outcomes (TVR, MACEs, ST) between these 2 types of stents during a 1-year follow-up period.\[22\] The LEADERS trial involving 1707 patients from 10 centers showed BP-DES to be noninferior to SES in terms of the primary endpoints at 5 years; however, BP-DES were associated with a significantly lower rate of very late (from 1 year to 5 years) ST than DP-SES.\[23\]

Nevertheless, other studies showed results that deviated partly or completely from this current analysis. For example, the meta-analysis published by Lv et al showed BP-DES to be safe, efficient, and exhibiting superior performance compared with DP-DES in terms of very late ST.\[24\] However, their study only involved first-generation BP-DES and the first-generation DP-DES. Another study showed BP-DES to be more effective in reducing MACEs and ST than DP-DES during the long term.\[25\] Even the study published by Zhu et al showed BP-DES to be associated with a lower rate of very late ST. However, the authors suggested further studies to confirm their findings. Nevertheless, even if BP-DES showed to be more effective than DP-DES, this efficacy was more visible only with SES.\[26\] But in this current study, even when SES were separately compared with BP-DES, no significant difference was observed.

However, these adverse outcomes might not always be dependent on the types of stents that were implanted. Several other studies have shown that the types of patients who were involved,\[27\] age of the patients, the comorbidities, and complications which were present before or following PCI,\[30–32\] the types of anti-platelets that were used,\[33,34\] the dosage of aspirin that was used,\[35\] could all contribute to and have a great impact on the adverse clinical outcomes following PCI.

Several studies have also shown bleeding risk to be affected by the duration of DAPT use. A decrease in major bleeding, without any increase in mortality or ST, has systematically been demonstrated with a shorter duration of DAPT (\(<6\) months).\[33\] In patients who were implanted with second-generation DES, abbreviated DAPT duration (\(\leq6\) months) was considered adequately protective with lower bleeding events.\[36\] One of the possible advantages of BP-DES is the decreased risk of late ST, hence, requiring a shorter duration of DAPT use, which is associated with less bleeding. In the RESOLVE trial, only 7 out of the 596 patients who were implanted with BP-DES reported major bleeding compared with 9 out of 596 patients who were implanted with DP-DES.\[15\]

This current analysis only involved first-generation DP-DES. Another study showed BP-DES to be more effective in reducing MACEs and ST than DP-DES during the long term.\[21\] Even the study published by Zhu et al showed BP-DES to be associated with a lower rate of very late ST. However, the authors suggested further studies to confirm their findings. Nevertheless, even if BP-DES showed to be more effective than DP-DES, this efficacy was more visible only with SES.\[26\] But in this current study, even when SES were separately compared with BP-DES, no significant difference was observed.

### Table 7

| Outcomes analyzed | OR with 95% CI | \( P \) | \( \hat{I} (%) \) |
|------------------|---------------|--------|--------|
| Mortality        | 0.84 [0.66–1.07] | .16 | 0 |
| MI               | 1.01 [0.45–2.27] | .98 | 0 |
| TLR              | 0.91 [0.75–1.11] | .37 | 0 |
| MACEs            | 0.86 [0.64–1.17] | .65 | 0 |
| Total ST         | 0.77 [0.50–1.18] | .22 | 0 |
| Definite ST      | 0.71 [0.43–1.18] | .19 | 0 |
| Probable ST      | 1.31 [0.56–3.08] | .53 | 6 |

CI = confidence interval, MACEs = major adverse cardiac events, MI = myocardial infarction, OR = odds ratios, ST = stent thrombosis, TLR = target lesion revascularization.
heterogeneity among the subgroups analyzing the long-term outcomes, low risk of bias, and highly conducted statistical analyses, and hence could be used in clinical medicine to predict prognosis in patients who were implanted with either BP-DES or first-generation DP-DES.

4.1. Limitations

This analysis also has limitations. First of all, due to the limited number of patients, the results of this analysis might be restricted in certain ways. Moreover, the long-term follow-up period was restricted to only 3 years. Further studies with longer follow-up periods would have been more interesting. Unfortunately, data with even longer follow-up periods were not available. In addition, MACEs were reported in only a few trials. Therefore, only a few trials were included in the subgroup analysis of long-term MACEs. This could also represent another limitation of this analysis. Also, the subgroup analyzing total ST included a combination of different types of ST with different definitions. However, heterogeneity was not observed, as most STs, which were reported, were definite and probable ST as defined.

Figure 8. Comparing BP-DES with first-generation DP-DES during a long-term follow-up period (≥2 years). Even during a long-term follow-up period, no significant difference was observed between BP-DES and first-generation DP-DES as shown in the figure.
by the ARC classification. In addition, the inclusion of a variety of patients with stable chronic CAD, unstable CAD (ST segment elevation myocardial infarction and non-ST segment elevated myocardial infarction) could also represent a limitation of this study. In addition, the duration of dual anti-platelet agents might also have had an effect on the results that were obtained.

5. Conclusion

Long-term mortality, MI, TLR, MACEs, and ST were not significantly different between BP-DES and the first-generation DP-DES. However, the follow-up period was restricted to only 3 years in this analysis.

References

[1] Cutlip DE, Abbott JD. Bioresorbable Polymer or Scaffold Drug-Eluting Coronary Artery Stents. Available at: https://www.uptodate.com/contents/bioresorbable-polymer-or-scaffold-drug-eluting-coronary-artery-stents.
[2] Marchini JF, Gomes WF, Moulin B, et al. Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trial. Cardiovasc Diagn Ther 2014;4:480–6.
[3] Piccolo R, Cassese S, Galasso G, et al. Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials. Clin Res Cardiol 2012;101:885–93.
[4] Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–51.
Bundhun et al. Medicine (2017) 96:47 www.md-journal.com

[5] Shen L, Yang W, Yin JS, et al. Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease. Chin Med J (Engl) 2015;128:768–73.

[6] Krucoff MW, Kereiakes DJ, Petersen JL, et al. COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary artery disease: primary results of the COSTAR (Cobalt Chromium Stent With Anti proliferative For Restenosis) II study. J Am Coll Cardiol 2008;51:1543–52.

[7] Yuan F, Chen X, Song X, et al. HOPE InvestigatorNovel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial. Chin Med J (Engl) 2014;127:2561–6.

[8] Han Y, Xu B, Jing Q, et al. I-LOVE-IT 2 Investigators. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents. JACC Cardiovasc Interv 2014;7:1352–60.

[9] Byrne RA, Kufner S, Tiroch K, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009;95:1489–94.

[10] Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011;58:1325–31.

[11] Klaus V, Serruys PW, Pilgrim T, et al. Two-year clinical follow-up from the randomized comparison of bioabsorbable stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. JACC Cardiovasc Interv 2011;4:887–95.

[12] Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI I trial-Phase 2. Circ Cardiovasc Interv 2009;2:188–95.

[13] Kadota K, Muramatsu T, Iwabuchi M, et al. Randomized comparison of the Nobori Biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012;80:789–96.

[14] Xu B, Dou K, Yang Y, et al. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial. EuroIntervention 2012;8:796–802.

[15] Zhang Q, Qiu JP, Kirtane AJ, et al. Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stent in patients with acute-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE study. J Interv Cardiol 2014;27:131–41.

[16] Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in selected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013;381:661–9.

[17] Higgin JPT, Altmann DG, Higgins JPT, Green S. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 2008;Wiley, 187–241.

[18] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

[19] Ye Y, Xie H, Zeng Y, et al. Efficacy and safety of biodegradable polymer Biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLoS One 2013;8:e78667.

[20] Zhang Y, Tian N, Dong S, et al. Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. Chin Med J (Engl) 2014;127:2539–66.

[21] Wang Y, Dong P, Li L, et al. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents for patients with coronary artery disease: an update meta-analysis. Cardiovasc Drugs Ther 2014;28:379–85.

[22] Buszman PP, Orlit B, Trela B, et al. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry. Catheter Cardiovasc Interv 2013;82:E155–62.

[23] Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013;6:777–89.

[24] Lv J, Wu Y, Zhang X, et al. Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. Eur J Med Res 2015;20:21.

[25] Wang Q, Zhou YU, Qiao T, et al. Clinical performance of biodegradable versus permanent polymer drug-eluting stents: a meta-analysis of randomized clinical trials at long-term follow-up. Exp Ther Med 2013;9:1543–50.

[26] Zhu L, Lv YN, Wang YL. Stent thrombosis with biodegradable polymer drug-eluting stents versus durable polymer sirolimus-eluting stents: an update meta-analysis. Cardiology 2015;130:96–105.

[27] Lupi A, Gabrio Secco G, Rognoni A, et al. Meta-analysis of biodegradable versus durable polymer drug-eluting stents in 20,003 patients with coronary artery disease: an update. Catheter Cardiovasc Interv 2014;83:e193–206.

[28] Bundhun PK, Li N, Chen MH. Does an obesity paradox really exist after cardiovascular intervention? A systematic review and meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore) 2015;94:e1910.

[29] Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol 2015;14:135.

[30] Bundhun PK, Wu ZJ, Chen MH. Impact of modifiable cardiovascular risk factors on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of 100 studies. Medicine (Baltimore) 2015;94:e2313.

[31] Bundhun PK, Boodhoo KD, Long MY, et al. Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3200.

[32] Bundhun PK, Bhurta A, Chen MH. Impact of coronary artery bypass surgery and percutaneous coronary intervention on mortality in patients with chronic kidney disease and on dialysis: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e4129.

[33] D’Ascenzo F, Moretti C, Bianco M, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol 2016;117:1714–23.

[34] Bundhun PK, Yanamula CM, Huang F. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord 2016;16:161.

[35] Bundhun PK, Janoo G, Treuluck AR, et al. Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:169.

[36] Ziaida KM, Abdel-Latif AK, Charnigo R, et al. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: a systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv 2016;87:22–32.